# Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

> **NCT02929797** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 72 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** CD8+NKG2D+ AKT Cell
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02929797
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2019-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2016-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929797, "Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02929797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*